Alembic Pharma Q2 FY27 Revenue Surges 36% to ₹2,603 Cr; US Generics Up 72%
Alembic Pharmaceuticals reported a 36% YoY revenue growth in Q2 FY27 to ₹2,603 crore. The US Generics business surged 72% YoY. The company raised its FY27 revenue growth guidance to 20-25%. An expanded collaboration with DifGen Pharmaceuticals was announced.
The significant revenue growth, improved profitability, raised future guidance, and strategic partnership in a key market like the US indicate a substantial positive impact on the company's financial performance and market position.
The company reported strong double-digit growth in revenue and improved profitability, exceeding expectations and raising future guidance. The expansion of a strategic collaboration also adds to the positive outlook.
Alembic Pharmaceuticals Limited announced strong financial results for the second quarter and first half of FY27. Consolidated revenue for Q2 FY27 reached ₹2,603 crore, marking a significant 36% year-on-year growth, driven by robust performance across all business segments.
The India business demonstrated a 14% year-on-year growth, with the Human Health segment returning to double-digit growth at 11%, supported by chronic and specialty therapies. The Animal Health segment continued its strong momentum, growing by 23%.
The U.S. Generics business reported exceptional growth, with revenue increasing by 72% year-on-year, aided by strong volume growth and contributions from new launches. The company also expanded its strategic collaboration with DifGen Pharmaceuticals, gaining access to a differentiated portfolio of over 20 complex generic products.
For the first half of FY27, consolidated revenue grew by 31% year-on-year to ₹4,753 crore. Reported EBITDA grew by 78% in Q2 FY27, with EBITDA margin expanding to 22.2% from 17% in the previous year.
Alembic Pharmaceuticals has raised its FY27 consolidated revenue growth guidance to 20%-25% from mid-teens, reflecting increased confidence in the U.S. and API businesses. The company expects the U.S. business to grow up to 40% year-on-year for the full year.
What to do with a filing like this
Alembic Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alembic Pharmaceuticals Limited. Read the original for the full detail.